Liquidia Technologies LQDA 深 滬
等待開盤 10-10 09:30:00 美东时间
24.25
+0.170
+0.71%
華盛通- 最 高24.46
- 今 開24.06
- 成交量 234.22万股
- 最 低 23.175
- 昨 收 24.08
- 總市值 20.88亿
- 52周最高 29.94
- 市盈率 靜 --
- 換手率 2.72%
- 52周最低 9.71
- 委 比 7.60%
- 總股本 8609.15万
- 歷史最高 38.46
- 量 比 0.98
- 振 幅 5.34%
- 歷史最低 2.25
- 每 手 1
- 風險率 4.98%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅4347.41%！Ascendiant Capital上调PAVmed目标价至20美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持PAVmed"买入"评级，目标价从19美元升至20美元；Ascendiant Capital：维持Plus Therapeutics"买入"评级，目标价从20.5美元升至21美元
10-07 15:04
Liquidia Corporation to Host R&D Day in New York City on October 28, 2025
Liquidia Corporation will host an R&D Day on October 28, 2025, in New York City, featuring presentations by its management and three key opinion leaders in pulmonary hypertension. The focus will be on L606, an investigational sustained-release treprostinil formulation, and YUTREPIA™, its approved inhaled treprostinil powder. The event aims to highlight progress in improving patient outcomes for those with pulmonary arterial hypertension (PAH) and...
10-07 10:30
HC Wainwright & Co. Reiterates Buy on Liquidia, Maintains $35 Price Target
HC Wainwright & Co. analyst Andrew S. Fein reiterates Liquidia (NASDAQ:LQDA) with a Buy and maintains $35 price target.
10-06 18:39
Liquidia to Present Clinical Data from ASCENT Trial at the CHEST 2025 Annual Meeting
Liquidia Corporation will present two oral reports at CHEST 2025 in Chicago on October 21, 2025. The reports focus on safety and efficacy data from the ASCENT trial for LIQ861 DPI treprostinil in PH-ILD patients, as well as observed changes in cardiac effort. The presentations will be delivered by Dr. Dan Lachant and Dr. Nicholas Kolaitis. The slides will be available on Liquidia’s website.
09-29 12:30
SA Asks: Which biotechs could be acquired by year's end?
The fourth quarter has historically been a busy time for the biopharma industry, with the sector generally seeing a significant uptick in M&A activity. We asked Seeking Alpha analysts Stephen Ayers ...
09-14 04:18
Liquidia Announces Poster Presentations at the Pulmonary Hypertension Professional Association (PHPN) Symposium
Liquidia Corporation will present four posters at the PHPN Symposium in Seattle on September 19, 2025. The posters include new safety and efficacy data on YUTREPIA™, a dry powder inhaled treprostinil, for PH-ILD patients, as well as previously published studies on its impact on cardiac effort, quality of life, and device misuse. The posters will be available on Liquidia’s website after the presentation.
09-11 12:30
Why Is United Therapeutics Stock Rallying On Tuesday?
United Therapeutics' Tyvaso showed significant lung function improvement in IPF patients, with plans to seek FDA approval for expanded use.
09-02 22:59
Liquidia Analysts Raise Their Forecasts Following Q2 Results
Liquidia Corporation (NASDAQ:LQDA) reported a loss for the second quarter on Tu...
08-14 02:51
Why Is Liquidia Stock Trading Higher On Tuesday?
Liquidia Q2 sales hit $8.84 million after Yutrepia launch; PH-ILD study shows stable tolerability and improved walking distance at week 16.
08-13 02:25
Liquidia shares are trading higher. The company reported Q2 financial results.
Liquidia shares are trading higher. The company reported Q2 financial results.
08-12 20:55
